Literature DB >> 32478838

Bayesian Interpretation of the EXCEL Trial and Other Randomized Clinical Trials of Left Main Coronary Artery Revascularization.

James M Brophy1.   

Abstract

Importance: Patients with left main coronary artery disease have improved outcomes with coronary revascularization compared with medical therapy, but the choice of optimal revascularization technique is unresolved. Objective: To use bayesian methods to analyze the risk differences for patients with left main coronary artery disease randomized to treatment with coronary artery bypass surgery (CABG) compared with those randomized to percutaneous coronary intervention (PCI) in recent randomized clinical trials (RCTs). Design, Setting, and Participants: A systematic review using the PubMed database with the query string "(left main disease) and (PCI or CABG) and (5-year follow-up) and (clinical trial)" identified all RCTs from January 1996 to January 2020 comparing CABG to PCI for treatment of patients with left main coronary artery disease and with 5-year follow-up data. With the use of bayesian methods, the largest and most publicized RCT (EXCEL; Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization; 2019) was reanalyzed (1) as an isolated entity using noninformative priors and (2) in the context of previous knowledge using informative priors derived from similar trials. Published aggregate data were used with assignments from each trial following the original intention-to-treat principle. Combining EXCEL data with varying levels of prior information using Bayes theorem provided final (posterior) probability distributions for primary and secondary outcomes. Main Outcomes and Measures: A composite end point of death, nonfatal myocardial infarction, and stroke was the primary EXCEL outcome and was accordingly the primary outcome for this reanalysis. Secondary analyses were performed for isolated all-cause mortality and for the composite outcome along with repeated revascularization procedures.
Results: When EXCEL data were analyzed using the originally stated noninferiority design, the 5-year primary outcome difference reported (2.8%; 95% CI, -0.9% to 6.5%) exceeded the predefined 4.2% noninferiority margin; thus, the null hypothesis of PCI inferiority could not be rejected. By contrast, the present bayesian analysis of the EXCEL primary outcome estimated 95% probability that the 5-year primary outcome difference was increased with PCI compared with CABG and 87% probability that this difference was greater than 1 extra event per 100 patients treated. Bayesian analyses also suggested 99% probability that EXCEL total mortality was increased with PCI and 94% probability that this absolute difference exceeded 1 extra deaths per 100 treated. A systematic review identified 3 other RCTs that studied the same question. The incorporation of this prior knowledge reduced the estimated probability of any excess mortality with PCI to 85%. For the secondary composite end point, which also included repeated revascularizations, there were estimated probabilities of 98% for at least 4 extra events and of 90% for at least 5 extra events per 100 patients treated with PCI. Conclusions and Relevance: Bayesian analysis assisted in RCT data interpretation and specifically suggested, whether based on EXCEL results alone or on the totality of available evidence, that PCI was associated with inferior long-term results for all events, including mortality, compared with CABG for patients with left main coronary artery disease.

Entities:  

Mesh:

Year:  2020        PMID: 32478838      PMCID: PMC7265123          DOI: 10.1001/jamainternmed.2020.1647

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


  15 in total

Review 1.  Methods in health service research. An introduction to bayesian methods in health technology assessment.

Authors:  D J Spiegelhalter; J P Myles; D R Jones; K R Abrams
Journal:  BMJ       Date:  1999-08-21

2.  Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial.

Authors:  Niels R Holm; Timo Mäkikallio; M Mitchell Lindsay; Mark S Spence; Andrejs Erglis; Ian B A Menown; Thor Trovik; Thomas Kellerth; Gintaras Kalinauskas; Lone Juul Hune Mogensen; Per H Nielsen; Matti Niemelä; Jens F Lassen; Keith Oldroyd; Geoffrey Berg; Peteris Stradins; Simon J Walsh; Alastair N J Graham; Petter C Endresen; Ole Fröbert; Uday Trivedi; Vesa Anttila; David Hildick-Smith; Leif Thuesen; Evald H Christiansen
Journal:  Lancet       Date:  2019-12-23       Impact factor: 79.321

3.  Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial.

Authors:  Friedrich W Mohr; Marie-Claude Morice; A Pieter Kappetein; Ted E Feldman; Elisabeth Ståhle; Antonio Colombo; Michael J Mack; David R Holmes; Marie-angèle Morel; Nic Van Dyck; Vicki M Houle; Keith D Dawkins; Patrick W Serruys
Journal:  Lancet       Date:  2013-02-23       Impact factor: 79.321

4.  Randomized Trial of Stents Versus Bypass Surgery for Left Main Coronary Artery Disease: 5-Year Outcomes of the PRECOMBAT Study.

Authors:  Jung-Min Ahn; Jae-Hyung Roh; Young-Hak Kim; Duk-Woo Park; Sung-Cheol Yun; Pil Hyung Lee; Mineok Chang; Hyun Woo Park; Seung-Whan Lee; Cheol Whan Lee; Seong-Wook Park; Suk Jung Choo; CheolHyun Chung; JaeWon Lee; Do-Sun Lim; Seung-Woon Rha; Sang-Gon Lee; Hyeon-Cheol Gwon; Hyo-Soo Kim; In-Ho Chae; Yangsoo Jang; Myung-Ho Jeong; Seung-Jea Tahk; Ki Bae Seung; Seung-Jung Park
Journal:  J Am Coll Cardiol       Date:  2015-03-15       Impact factor: 24.094

5.  Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial.

Authors:  Daniel J F M Thuijs; A Pieter Kappetein; Patrick W Serruys; Friedrich-Wilhelm Mohr; Marie-Claude Morice; Michael J Mack; David R Holmes; Nick Curzen; Piroze Davierwala; Thilo Noack; Milan Milojevic; Keith D Dawkins; Bruno R da Costa; Peter Jüni; Stuart J Head
Journal:  Lancet       Date:  2019-09-02       Impact factor: 79.321

6.  Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease.

Authors:  Gregg W Stone; Joseph F Sabik; Patrick W Serruys; Charles A Simonton; Philippe Généreux; John Puskas; David E Kandzari; Marie-Claude Morice; Nicholas Lembo; W Morris Brown; David P Taggart; Adrian Banning; Béla Merkely; Ferenc Horkay; Piet W Boonstra; Ad J van Boven; Imre Ungi; Gabor Bogáts; Samer Mansour; Nicolas Noiseux; Manel Sabaté; José Pomar; Mark Hickey; Anthony Gershlick; Pawel Buszman; Andrzej Bochenek; Erick Schampaert; Pierre Pagé; Ovidiu Dressler; Ioanna Kosmidou; Roxana Mehran; Stuart J Pocock; A Pieter Kappetein
Journal:  N Engl J Med       Date:  2016-10-31       Impact factor: 91.245

7.  Placing trials in context using Bayesian analysis. GUSTO revisited by Reverend Bayes.

Authors:  J M Brophy; L Joseph
Journal:  JAMA       Date:  1995-03-15       Impact factor: 56.272

8.  Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease.

Authors:  Gregg W Stone; A Pieter Kappetein; Joseph F Sabik; Stuart J Pocock; Marie-Claude Morice; John Puskas; David E Kandzari; Dimitri Karmpaliotis; W Morris Brown; Nicholas J Lembo; Adrian Banning; Béla Merkely; Ferenc Horkay; Piet W Boonstra; Ad J van Boven; Imre Ungi; Gabor Bogáts; Samer Mansour; Nicolas Noiseux; Manel Sabaté; Jose Pomar; Mark Hickey; Anthony Gershlick; Pawel E Buszman; Andrzej Bochenek; Erick Schampaert; Pierre Pagé; Rodrigo Modolo; John Gregson; Charles A Simonton; Roxana Mehran; Ioanna Kosmidou; Philippe Généreux; Aaron Crowley; Ovidiu Dressler; Patrick W Serruys
Journal:  N Engl J Med       Date:  2019-09-28       Impact factor: 91.245

9.  Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease.

Authors:  Patrick W Serruys; Marie-Claude Morice; A Pieter Kappetein; Antonio Colombo; David R Holmes; Michael J Mack; Elisabeth Ståhle; Ted E Feldman; Marcel van den Brand; Eric J Bass; Nic Van Dyck; Katrin Leadley; Keith D Dawkins; Friedrich W Mohr
Journal:  N Engl J Med       Date:  2009-02-18       Impact factor: 91.245

10.  Five-year outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in the synergy between percutaneous coronary intervention with taxus and cardiac surgery trial.

Authors:  Marie-Claude Morice; Patrick W Serruys; A Pieter Kappetein; Ted E Feldman; Elisabeth Ståhle; Antonio Colombo; Michael J Mack; David R Holmes; James W Choi; Witold Ruzyllo; Grzegorz Religa; Jian Huang; Kristine Roy; Keith D Dawkins; Friedrich Mohr
Journal:  Circulation       Date:  2014-04-03       Impact factor: 29.690

View more
  6 in total

1.  Genotype-Guided P2Y12 Inhibitor Therapy After Percutaneous Coronary Intervention: A Bayesian Analysis.

Authors:  Vibhu Parcha; Brittain F Heindl; Peng Li; Rajat Kalra; Nita A Limdi; Naveen L Pereira; Garima Arora; Pankaj Arora
Journal:  Circ Genom Precis Med       Date:  2021-10-21

2.  Revascularisation strategies in patients with significant left main coronary disease during the COVID-19 pandemic.

Authors:  Mohamed O Mohamed; Nick Curzen; Mark de Belder; Andrew T Goodwin; James C Spratt; Lognathen Balacumaraswami; John Deanfield; Glen P Martin; Muhammad Rashid; Ahmad Shoaib; Chris P Gale; Tim Kinnaird; Mamas A Mamas
Journal:  Catheter Cardiovasc Interv       Date:  2021-03-25       Impact factor: 2.585

3.  Bayesian survival analysis for early detection of treatment effects in phase 3 clinical trials.

Authors:  Lucie Biard; Anne Bergeron; Vincent Lévy; Sylvie Chevret
Journal:  Contemp Clin Trials Commun       Date:  2021-01-09

4.  Using Bayesian Methods to Augment the Interpretation of Critical Care Trials. An Overview of Theory and Example Reanalysis of the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial.

Authors:  Fernando G Zampieri; Jonathan D Casey; Manu Shankar-Hari; Frank E Harrell; Michael O Harhay
Journal:  Am J Respir Crit Care Med       Date:  2021-03-01       Impact factor: 21.405

5.  Mortality Rates Among Hospitalized Patients With COVID-19 Infection Treated With Tocilizumab and Corticosteroids: A Bayesian Reanalysis of a Previous Meta-analysis.

Authors:  Arthur M Albuquerque; Lucas Tramujas; Lorenzo R Sewanan; Donald R Williams; James M Brophy
Journal:  JAMA Netw Open       Date:  2022-02-01

6.  Single or multiple arterial bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel or left main coronary artery disease.

Authors:  Piroze M Davierwala; Chao Gao; Daniel J F M Thuijs; Rutao Wang; Hironori Hara; Masafumi Ono; Thilo Noack; Scot Garg; Neil O'leary; Milan Milojevic; Arie Pieter Kappetein; Marie-Claude Morice; Michael J Mack; Robert-Jan van Geuns; David R Holmes; Mario Gaudino; David P Taggart; Yoshinobu Onuma; Friedrich Wilhelm Mohr; Patrick W Serruys
Journal:  Eur Heart J       Date:  2022-03-31       Impact factor: 29.983

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.